NCT07125222 - Use of Gocovri to Improve Disability Due to Radiation Encephalopathy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

August 31, 2028

Study Completion Date

August 31, 2028

Conditions

Radiation Encephalopathy

Interventions

DRUG

Gocovri (extended-release amantidine)

Gocovri is extended release formulation of amantidine. Starting on Day 1, patients will start Gocovri 137mg daily. If there is no dose-limited event after 28 days, the dose will be increased to 274mg daily which will become the new standard dose for the remaining 20 weeks of the patient's participation in the study.

Trial Locations (1)

10065

Weill Cornell Medicine, New York